Louis Chesler

Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform

Rafal Panek, Hannah Webber, Gilberto S Almeida, 2017, British Journal of Cancer.

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease

Florence I. Raynaud, Kevin Petrie, William A. Weiss, 2015, Cancer cell.

Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.

Sergey Popov, Dow-Mu Koh, Chris Jones, 2013, Radiology.

Subclonal reconstruction of tumors using machine learning and population genetics

Giulio Caravagna, Guido Sanguinetti, Benjamin Werner, 2020, Nature Genetics.

Implementation of mechanism of action biology-driven early drug development for children with cancer.

Gudrun Schleiermacher, Hubert Caron, Birgit Geoerger, 2016, European journal of cancer.

Regulation of transforming growth factor b1 by nitric oxide

Yoram Vodovotz, Mary Helen Barcellos-Hoff, Anita B. Roberts, 1999 .

Challenges to curing primary brain tumours

Giles W. Robinson, Paul Workman, Amar Gajjar, 2019, Nature Reviews Clinical Oncology.

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

Bandana Sharma, Wenchao Wang, Nathanael S Gray, 2012, Cancer cell.